Unknown

Dataset Information

0

Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery.


ABSTRACT: The emerging discipline of bacterial glycoengineering has made it possible to produce designer glycans and glycoconjugates for use as vaccines and therapeutics. Unfortunately, cell-based production of homogeneous glycoproteins remains a significant challenge due to cell viability constraints and the inability to control glycosylation components at precise ratios in vivo. To address these challenges, we describe a novel cell-free glycoprotein synthesis (CFGpS) technology that seamlessly integrates protein biosynthesis with asparagine-linked protein glycosylation. This technology leverages a glyco-optimized Escherichia coli strain to source cell extracts that are selectively enriched with glycosylation components, including oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs). The resulting extracts enable a one-pot reaction scheme for efficient and site-specific glycosylation of target proteins. The CFGpS platform is highly modular, allowing the use of multiple distinct OSTs and structurally diverse LLOs. As such, we anticipate CFGpS will facilitate fundamental understanding in glycoscience and make possible applications in on demand biomanufacturing of glycoproteins.

SUBMITTER: Jaroentomeechai T 

PROVIDER: S-EPMC6043479 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Single-pot glycoprotein biosynthesis using a cell-free transcription-translation system enriched with glycosylation machinery.

Jaroentomeechai Thapakorn T   Stark Jessica C JC   Natarajan Aravind A   Glasscock Cameron J CJ   Yates Laura E LE   Hsu Karen J KJ   Mrksich Milan M   Jewett Michael C MC   DeLisa Matthew P MP  

Nature communications 20180712 1


The emerging discipline of bacterial glycoengineering has made it possible to produce designer glycans and glycoconjugates for use as vaccines and therapeutics. Unfortunately, cell-based production of homogeneous glycoproteins remains a significant challenge due to cell viability constraints and the inability to control glycosylation components at precise ratios in vivo. To address these challenges, we describe a novel cell-free glycoprotein synthesis (CFGpS) technology that seamlessly integrate  ...[more]

Similar Datasets

| S-EPMC8733600 | biostudies-literature
| S-EPMC10450168 | biostudies-literature
| S-EPMC6700315 | biostudies-literature
| S-EPMC7445873 | biostudies-literature
| S-EPMC9245472 | biostudies-literature
| S-EPMC5976856 | biostudies-literature
| S-EPMC4850263 | biostudies-literature
| S-EPMC6881289 | biostudies-literature
| S-EPMC8672043 | biostudies-literature
| S-EPMC4108260 | biostudies-literature